Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Andrew Spencer, MD, Sung-Soo Yoon, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Shannon Morris, MD, PhD, Deborah Smith, PharmD, Steven J. Freedman, MD, PhD, Richard Brigandi, MD, PhD, Allen Oliff, MD, Joanna B. Opalinska, MD, PhD, Christine Chen, MD

Blood (2011) 118 (21): 1856.

https://doi.org/10.1182/blood.V118.21.1856.1856

Published: 2011

Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

Francis Giles, MD, Jorge Cortes, MD, Donald A. Bergstrom, MD, PhD, Alan Xiao, PhD, Dan Jones, MD, PhD, Srdan Verstovsek, MD, PhD, Deborah Thomas, MD, Hagop M. Kantarjian, MD, Steven J. Freedman, MD, PhD

Blood (2006) 108 (11): 253.

https://doi.org/10.1182/blood.V108.11.253.253

Published: 2006

Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.

Francis Giles, MD, Steven J. Freedman, MD,PhD, Alan Xiao, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, William Wierda, MD,PhD, Steven M. Kornblau, MD, Susan O’Brien, MD, Donald A. Bergstrom, MD,PhD, David A. Rizzieri, MD

Blood (2006) 108 (11): 1967.

https://doi.org/10.1182/blood.V108.11.1967.1967

Published: 2006

Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

Donald A. Bergstrom, MD, PhD, Jason B. Clark, PhD, Alan Xiao, PhD, Matthew Griffiths, PhD, Susannah Falcon, PhD, John Pollard, PhD, Steven J. Freedman, MD,PhD, Francis Giles, MD

Blood (2006) 108 (11): 637.

https://doi.org/10.1182/blood.V108.11.637.637

Published: 2006

Journal Articles

MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).

Francis Giles, MD, Donald A. Bergstrom, MD,PhD, Guillermo Garcia-Manero, MD, Steven Kornblau, MD, Michael Andreeff, MD,PhD, Hagop Kantarjian, MD, Dan Jones, MD,PhD, Steven J. Freedman, MD,PhD, Srdan Verstovsek, MD,PhD

Blood (2006) 108 (11): 4893.

https://doi.org/10.1182/blood.V108.11.4893.4893

Published: 2006

Journal Articles

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).

Francis Giles, MD, Jorge Cortes, MD, Donald A. Bergstrom, MD, PhD, Alan Xiao, PhD, Penny Bristow, Dan Jones, MD, PhD, Srdan Verstovsek, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Steven J. Freedman, MD, PhD

Blood (2006) 108 (11): 163.

https://doi.org/10.1182/blood.V108.11.163.163

Published: 2006

NARROW

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only